The much anticipated reorganisation of AIFA has been postponed again, according to the local press. A new amendment to the National Recovery and Resilience Plan, (Piano Nazionale di Ripresa e Resilienza) grants a further extension of the membership of the Technical and Scientific Committee (CTS) and the Pricing and Reimbursement Committee (CPR) until 31st December 2022 (it had been due to expire on 30th June 2022, having already been extended previously).
It is widely expected that the reform will entail the unification of the CTS and the CPR into one body called the Scientific and Economic Commission of Medicines (CSE). It is expected that the CSE will be responsible for both the scientific assessment and the price negotiation of medicines. The rationale behind the unification of CTS and CPR is to better integrate and align the two functions, avoiding unnecessary overlap and duplication of efforts, in order to streamline and accelerate the pricing and reimbursement process.
www.quotidianosanita.it , “Aifa: pronta la proroga di Cts e Cpr fino al 31 dicembre 2022”, 17/06/2022
www.pphc.it, “Governance del farmaco, le sfide per il 2022”, 24/01/2022
www.repubblica.it, “Gli scontri dentro l’Aifa e il ministero che non interviene”, 15/02/2022
www.affaritaliani.it, “Verso la riforma dell’Aifa: la lotta di potere nell’Agenzia del Farmaco”, 18/02/2022